Neopterin serum levels in pancreatic adenocarcinoma

International Journal of Pancreatology

Volumn 25, Issue 1, 1999, Pages 31-37

  Manes, Gianpiero ^a   Spada, Orlando Antonio ^b   Rabitti, Pier Giorgio ^a   Feola, Bianca ^c   Misso, Saverio ^c   Minerva, Antonio ^c   Uomo, Generoso ^a,b  

^a Dept Gastroenterol Cardarelli H   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c City Hospital   (Italy)

Author keywords

Ca 19 9; Interleukin 6; Neopterin; Pancreatic cancer; Soluble interleukin 2 receptors; Tumor necrosis factor

Indexed keywords

CA 19-9 ANTIGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; NEOPTERIN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER IMMUNOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOMODULATION; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

EID: 0032928499     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:25:1:31     Document Type: Article

References (21)

1. 1 Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987; 60: 2284-2303.
2. 2 Müller MM, Curtius HC, Herold M, Hüber CH. Neopterin in clinical practice. Clin Chim Acta 1991; 201: 1-16.
3. 3 Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as a marker for activation of cellular immunity: immunological basis and clinical application. Adv Clin Chem 1989; 27: 81-141.
4. 4 Wachter H, Fuchs D, Hausen A, Reibnegger G, Weiss G, Werner ER, et al. Neopterin: Biochemistry, Methods, Clinical Application. Walter de Gruyter, Berlin, 1992.
5. 5 Vomo G, Spada O, Manes G, Feola B, Misso S, Cavallera A, Rabitti PG. Neopterin in acute pancreatitis. Scand J Gastroenterol 1996; 31: 1037-1039.
6. 6 Reibnegger G, Fuchs D, Fuith LC, Hausen A, Werner-ER, Werner-Felmayer G, et al. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 1991; 15: 483-489.
7. 7 Hausen A, Fuchs D, Reibnegger G, Wener ER, Wachter H. Neopterin in clinical use. Pteridines 1989; 1: 3-10.
8. 8 Haglund B, Roberts PJ, Kuusela P, Scheinin TM, Mäkelä O, Jalanko H. Evaluation of Ca 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 1986; 53: 197-202.
9. 9 Werner ER, Werner-Felmayer G, Fuchs D, Hausen G, Reibnegger G, Wachter H. Tertrahydrobiopterin biosinthetic activation in human macrophages, fibroblasts, TPH-1 and T24 cells. J Biol Chem 1990; 265: 3188-3192.
10. 10 Reibnegger GJ, Bichler AH, Dapunt O, Fuchs DN, Fuith LC, Hausen A, et al. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res 1986; 46: 950-955.
11. 11 Reibnegger G, Hetzel H, Fuchs D, Fuith LC, Hausen A, Werner ER, et al. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res 1987; 47: 4977-4981.
12. 12 Lawenhaupt A, Ekman P, Eneroth P, Erikkson A, Nilsson B, Nordström L. Serum levels of neopterin as related to the prognosis of human prostatic carcinoma. Eur Urol 1986; 12: 422-425.
13. 13 Kawasaki H, Watanabe H, Yamada S, Watanabe K, Suyama A. Prognostic significance of urinary neopterin levels in patients with hepatocellular carcinoma. Tohoku J Exp Med 1988; 155: 311-318.
14. 14 Denz H, Grünewald K, Thaler J, Huber H, Fuchs D, Hausen A, et al. Urinary neopterin as a prognostic marker in haematological neoplasias. Pteridines 1989; 1: 167-170.
15. 15 Lissoni P, Brivio F, Fumagalli L, Galimberti C, Cataldo M, Marsili MT, et al. A study of interactions among markers of macrophage function in metatstatic solid tumor: neopterin levels in relation to those of tumor necrosis-alpha and of soluble interleukin-2 receptors. J Biol Regul Homeost Agents 1994; 8: 32-35.
16. 16 Schmielau J, Kalthoff H, Roeder C, Schmiegel W. Cytokines and the biology of pancreatic cancer, in Pancreatic Cancer - Molecular and Clinical Advances. Neoptolemos JP, Lemoine NR, eds. Blackwell Science 1996; pp. 36-50.
17. 17 Zorn U, Dellmann I, Grosse J, Kirchner H, Paliwoda H, Atzpodien J. Soluble interleukin-2 receptors abrogate IL-2 induced activation of peripheral mononuclear cells. Cytokine 1994; 6: 358-364.
18. 18 Pezzilli R, Billi P, Beltrandi E, Mancini R, Casadei-Maldini M, Casadei R, et al. Serum soluble interleukin-2 receptor in pancreatic cancer and chronic pancreatitis. Ital J Gastroenterol 1994; 26: 137-140.
19. 19 Lissoni P, Barni S, Rovelli F, Viviani S, Maestroni GJ Conti A, et al. The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer 1990; 26: 33-36.
20. 20 Falconer JS, Fearon KCH, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expediture in cachectic patients with pancreatic cancer. Ann Surg 1994; 219: 325-331.
21. 21 Blay JK, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum levels of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-3322.